MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer

Standard-of-care for resectable gastric/gastroesophageal junction cancer includes surgery and neoadjuvant-adjuvant 5-fluorouracil-leucovorin-oxaliplatin-docetaxel (FLOT) chemotherapy. Early-phase clinical studies support further clinical development of the immune checkpoint inhibitor (ICI); durvalum...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Future oncology (London, England) Jg. 18; H. 20; S. 2465
Hauptverfasser: Janjigian, Yelena Y, Van Cutsem, Eric, Muro, Kei, Wainberg, Zev, Al-Batran, Salah-Eddin, Hyung, Woo Jin, Molena, Daniela, Marcovitz, Michelle, Ruscica, Dario, Robbins, Scott H, Negro, Alejandra, Tabernero, Josep
Format: Journal Article
Sprache:Englisch
Veröffentlicht: England 01.06.2022
Schlagworte:
Adenocarcinoma - pathology
Antibodies, Monoclonal
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Clinical Trials, Phase III as Topic
Esophagogastric Junction - pathology
Fluorouracil - adverse effects
Humans
Neoadjuvant Therapy
Randomized Controlled Trials as Topic
Stomach Neoplasms - pathology
neoadjuvant-adjuvant
resectable
durvalumab
gastric cancer
immunotherapy
PD-L1
gastroesophageal junction cancer
immune checkpoint inhibitors
chemotherapy
ISSN:1744-8301, 1744-8301
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Standard-of-care for resectable gastric/gastroesophageal junction cancer includes surgery and neoadjuvant-adjuvant 5-fluorouracil-leucovorin-oxaliplatin-docetaxel (FLOT) chemotherapy. Early-phase clinical studies support further clinical development of the immune checkpoint inhibitor (ICI); durvalumab, an anti-PD-L1 antibody, in patients with gastric/gastroesophageal junction cancer. Accumulating evidence indicates that ICIs combined with FLOT chemotherapy improve clinical outcomes in patients with advanced or metastatic cancer. We describe the rationale for and the design of MATTERHORN, a randomized, double-blind, placebo-controlled, phase III study investigating the efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy followed by adjuvant durvalumab monotherapy in patients with resectable gastric/gastroesophageal junction cancer. The planned sample size is 900 patients, the primary end point is event-free survival and safety and tolerability will be evaluated. Clinical trial registration: NCT04592913 (ClinicalTrials.gov).
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:1744-8301
1744-8301
DOI:10.2217/fon-2022-0093